Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1942 as adjunctive therapy in mild to moderate Alzheimer's Disease
NCT05602727Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of MK-1942 in Alzheimer's disease (AD), sponsored by Merck & Co.. Started Dec 2022; status: terminated.
02
Drugs
MK-1942
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05602727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05602727.